Safety and immunogenicity of a novel multiple antigen pneumococcal vaccine in adults: A Phase 1 randomised clinical trial.

CONCLUSIONS: All dose levels were considered safe and well tolerated. There was a statistically significant increase in anti-PnuBioVax IgG titres at the 200 and 500 µg dose levels compared to 50 µg and placebo. TRIAL REGISTRATION NUMBER: NCT02572635https://www.clinicaltrials.gov. PMID: 29132988 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/29132988?dopt=Abstract

Source: Vaccine - November 10, 2017 Category: Allergy & Immunology Authors: Entwisle C, Hill S, Pang Y, Joachim M, McIlgorm A, Colaco C, Goldblatt D, De Gorguette D'Argoeuves P, Bailey C Tags: Vaccine Source Type: research